false 0001739426 00-0000000 0001739426 2023-12-19 2023-12-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares





Washington, D.C. 20549





Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): December 19, 2023


RVL Pharmaceuticals plc

(Exact name of registrant as specified in its charter)


Ireland 001-38709 Not Applicable
(State or other jurisdiction
of incorporation)  
  (Commission File Number)     (IRS Employer
Identification No.)


400 Crossing Boulevard
, NJ
(Address of principal executive offices)   (Zip Code)


(Registrant’s telephone number, including area code): (908) 809-1300


Not Applicable

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which
Ordinary Shares   RVLPQ   N/A


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x






Item 5.07 Submission of Matters to a Vote of Security Holders.


At the extraordinary general meeting of shareholders of RVL Pharmaceuticals plc (the “Company”), held on December 19, 2023, the Company’s shareholders did not approve the proposal to authorize the Board of Directors of the Company (the “Board”) to petition the Irish High Court for an order to wind up the Company, which required the affirmative vote of the holders of ordinary shares representing at least 75% of the votes cast on the matter, based on the following votes:


For   Against   Abstain 
20,429,771   12,373,917   312,558 


Notwithstanding the above, the Board still intends to pursue a winding up of the Company.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: December 20, 2023 By: /s/ Brian Markison
    Brian Markison
    Chief Executive Officer



Dec. 19, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 19, 2023
Entity File Number 001-38709
Entity Registrant Name RVL Pharmaceuticals plc
Entity Central Index Key 0001739426
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code L2
Entity Address, Address Line One 400 Crossing Boulevard
Entity Address, City or Town Bridgewater
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08807
City Area Code 908
Local Phone Number 809-1300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary Shares
Trading Symbol RVLPQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true

RVL Pharmaceuticals (NASDAQ:RVLP)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more RVL Pharmaceuticals Charts.
RVL Pharmaceuticals (NASDAQ:RVLP)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more RVL Pharmaceuticals Charts.